Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance

スポンサーリンク

概要

• 論文の詳細を見る
• 2000-10-01

著者

• Saitoh Satoshi

  Department Of Hepatology Toranomon Hospital

• Saitoh Satoshi

  国家公務員共済組合連合会虎の門病院 肝臓内科

• KUMADA Hiromitsu

  Department of Hepatology, Toranomon Hospital

• Kumada Hiromitsu

  Department Of Gastroenterology Toranomon Hospital

• Saitoh S

  Department Of Hepatology Toranomon Hospital

• IKEDA Kenji

  Department of Hepatology, Toranomon Hospital

• MURASHIMA NAOYA

  Department of Gastroenterology, Toranomon Hospital

• Chayama Kazuaki

  Department Of Medicine And Molecular Science Graduate School Of Science Hiroshima University

• Chayama Kazuaki

  Hiroshima Univ. Hiroshima Jpn

• Chayama K

  Toranomon Hospital Tokyo Jpn

• Chayama K

  Department Of Medicine And Molecular Science Graduate School Of Biomedical Sciences Hiroshima Univer

• Chayama Kazuaki

  First Department Of Internal Medicine Faculty Of Medicine Hiroshima University

• Kobayashi M

  Department Of Hepatology Toranomon Hospital

• Matsuda M

  Research Institute For Hepatology Toranomon Branch Hospital

• Chayama Kazuaki

  Deparmtment Of Gastroenterology Toranomon Hospital

• KOBAYASHI MARIKO

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• ARASE YASUJI

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• CHAYAMA KAZUAKI

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• KOBAYASHI MASAHIRO

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• TSUBOTA AKIHITO

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• SAITOH SATOSHI

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• MURASHIMA NAOYA

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• MATSUDA MARIE

  Liver Research Laboratory and Department of Gastroenterology, Toranomon Hospital

• Murashima Naoya

  Department Of Gastroenterology Toranomon Hospital

• SUZUKI YOSHIYUKI

  Liver Research Laboratory, Toranomon Hospital

• HAGIWARA MIKA

  Liver Research Laboratory, Toranomon Hospital

• HASHIMOTO RIE

  Liver Research Laboratory, Toranomon Hospital

• NAKAGAWA MIKI

  Liver Research Laboratory, Toranomon Hospital

• Suzuki Yoshiyuki

  Department Of Hepatology Toranomon Hospital

• Matsuda Marie

  Department Of Surgery Toranomon Hospital

• Ikeda Kenji

  Department Of Bio-medical Engineering Tokai University

• Hagiwara Mika

  Liver Research Laboratory Toranomon Hospital

• Nakagawa Miki

  Liver Research Laboratory Toranomon Hospital

• Hashimoto Rie

  Liver Research Laboratory Toranomon Hospital

• Chayama Kazuaki

  First Department Of Internal Medicine Hiroshima University School Of Medicine

• Ikeda Kenji

  Department Of Applied Chemistry And Bioengineering Graduate School Of Engineering Osaka City Univers

• Ikeda Kenji

  Department De Genie Chimique Universite Nationale De Yokohama

関連論文

• Efficacy and Safety of Combination Therapy of Natural Human Interferon β and Ribavirin in Chronic Hepatitis C Patients with Genotype 2 and High Virus Load
• Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C Patients with Genotype 1b and High Virus Load
• Guidelines for the antiviral therapy of hepatitis C virus carriers with normal serum aminotransferase based on platelet counts
• Timing of interferon therapy and sources of infection in patients with acute hepatitis C
• Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin
• The Efficacy of Interferon-beta Monotherapy for Elderly Patients with Type C Hepatitis of Genotype 2
• Potential of laparoscopy in chronic liver disease with hepatitis B and C viruses
• Inhibitory effect of branched-chain amino acid granules on progression of compensated liver cirrhosis due to hepatitis C virus
• Hepatocarcinogenesis Following HCV RNA Eradication by Interferon in Chronic Hepatitis Patients
• The Efficacy of Short-Term Interferon-Beta Therapy for Type C Cirrhotic Patients with Genotype 2a and Low Virus Load
• Factors associated with the virological response of lamivudine-resistant hepatitis B virus during combination therapy with adefovir dipivoxil plus lamivudine
• Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma : a pilot study of patients with hepatitis B virus-related cirrhosis
• Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection
• Cost-effectiveness of radiofrequency ablation and surgical therapy for small hepatocellular carcinoma of 3cm or less in diameter
• Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C
• Efficacy of lamivudine treatment in Japanese patients with hepatitis B virus-related cirrhosis
• Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in Japan
• Infection with hepatitis B virus genotype A in Tokyo, Japan during 1976 through 2001
• Interferon monotherapy for patients with chronic hepatitis C and normal serum aminotransferase levels at commencement of treatment
• Factors contributing of ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C
• Peripheral CD8+/CD25+ lymphocytes may be implicated in hepatocellular injuries in patients with acute-onset autoimmune hepatitis
• Hepatocellular carcinoma in noncirrhotic young adult patients with chronic hepatitis B viral infection
• Efficacy of interferon retreatment after relapse for chronic hepatitis C patients with biochemical response after first interferon therapy
• Successful control of ruptured hepatocellular carcinoma with radiofrequency ablation
• Effectiveness of combination therapy of splenectomy and long-term interferon in patients with hepatitis C virus-related cirrhosis and thrombocytopenia
• Clinicopathological features, background liver disease, and survival analysis of HCV-positive patients with hepatocellular carcinoma : differences between young and elderly patients
• Changes in viral loads of lamivudine-resistant mutants during entecavir therapy
• Efficacy and anticarcinogenic activity of interferon for hepatitis C virus-related compensated cirrhosis in patients with genotype 1b low viral load or genotype 2
• Evaluation of long-term biochemical responses to combination therapy of interferon plus ribavirin in those infected with hepatitis C virus genotype 1b and high baseline viral load
• Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection
• Type C-chronic hepatitis patients who had autoimmune phenomenon and developed jaundice during interferon therapy
• A randomized, double-blind, controlled trial of natural interferon-β therapy for e-antigen-negative chronic hepatitis B patients with abnormal transaminase levels
• Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis
• High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load
• Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine
• Usefulness of serum KL-6 for early diagnosis of idiopathic pulmonary fibrosis in patients with hepatitis C virus
• Predictive values of amino acid sequences of the core and NS5A regions in antiviral therapy for hepatitis C : a Japanese multi-center study
• Nucleotide sequences of hepatitis GB virus C. Identification of highly conserved domains in the 5' noncoding region and detection by polymerase chain reaction
• Repeated administration of recombinant human serum albumin caused no serious allergic reactions in patients with liver cirrhosis : a multicenter clinical study
• Therapeutic effects of stronger neo-minophagen C at different doses on chronic hepatitis and liver cirrhosis
• Involvement of GBV-C/HGV in liver diseases in Japan
• Clinical features of hepatitis B virus genotype A in Japanese patients
• Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load
• Randomized contolled clinical trial of lymphoblastoid interferon-α for chronic hepatitis C
• Incidence of the appearance of the red color sign on esophageal varices and its predictive factors : long-term observations of 359 patients with cirrhosis
• Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen
• Interferon therapy for flare-up of hepatitis B virus infection after emergence of lamivudine-induced YMDD motif mutant
• Efficacy of IFN therapy based on duration period of negative HCV-RNA during IFN administration
• Distinction between chronic hepatitis and liver cirrhosis in patients with hepatitis C virus infection. Practical discriminant function using common laboratory data
• Progressive and sufficient decrease of hepatitis B core antibody can predict the disappearance of hepatitis B virus DNA in Japanese patients with hepatitis B surface antigen clearance
• Increased response rate to interferon therapy after a second course in hepatitis C patients who show relapse after the initial course
• Hepatic vascular side effects of styrene maleic acid neocarzinostatin in the treatment of hepatocellular carcinoma
• Fluctuation patterns of HCV-RNA serum level in patients with chronic hepatitis C
• A Device for Simultaneous Application of Sclerotherapy and Endoscopic Ligation for Management of Esophageal Varices
• Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy
• Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6
• Effect of arterial administration of a high-molecular weight antitumor agent, styrene maleic acid neocarzinostatin, in embolization-resistant liver cancer
• Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon α
• Relationship of hepatocellular carcinogenesis with precore mutant virus and serum hepatitis B virus DNA concentration A longitudinal analysis of patients with cirrhosis
• Detection of Hantaviral Antibodies among Patients with Hepatitis of Unknown Etiology in Japan
• Efficacy of interferon therapy for aged patients with chronic hepatitis C
• Effect of arterial administration of a high molecular weight anti-tumor agent, styrene maleic acid neocarzinostatin, for multiple small liver cancer - A pilot study
• The Superiority of Laparoscopic Examination in Predicting Hepatocellular Carcinoma after Inteferon Therapy for Chronic Type C Hepatitis
• Hepatitis C virus subtype 3b infection in a hospital Japan: Epidemiological study
• Novel Hepatitis B variants in sibling carriers postitive for antibody to hepatitis B surface antigen
• Usefulness of HCV-RNA counts by the method of HCV-bDNA probe in interferon retreatment for patients with HCV-RNA positive chronic hepatitis C
• A Pilot Study of Thymosin α_1 Therapy for Chronic Hepatitis B Patients
• Significance of multicentric cancer recurrence after potentially curative ablation of hepatocellular carcinoma : a longterm cohort study of 892 patients with viral cirrhosis
• Randomized trial of prolonged interferon retreatment for chronic hepatitis C patients with HCV-genotype 1b and high virus load
• Serum levels of γ-globulin and total bilirubin influence the prevalence of multiple extrahepatic complication in patients with hepatitis C virus infection
• Randomized, controlled trial of natural interferon-α therapy for e-antigen-positive chronic hepatitis B patients
• Clinical characteristics of patients infected with hepatitis B virus genotypes A, B, and C
• The Development of Chronic Kidney Disease in Japanese Patients with Non-alcoholic Fatty Liver Disease
• Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants
• Rapid loss of hepatitis C virus genotype 1b from serum in patients receiving a triple treatment with telaprevir (MP-424), pegylated interferon and ribavirin for 12 weeks
• Management of hepatitis C ; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)
• Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment
• Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis C virus infection for the fiscal year 2008 in Japan
• Guidelines for the treatment of chronic hepatitis and cirrhosis due to hepatitis B virus infection for the fiscal year 2008 in Japan
• Effects of structural variations of APOBEC3A and APOBEC3B genes in chronic hepatitis B virus infection
• Multivariate analysis of risk factors for the development of type 2 diabetes in nonalcoholic fatty liver disease
• Interferon and lamivudine monotherapy on chronic hepatitis B in Japan
• Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan
• New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma
• Psychiatric symptoms related to interferon therapy for chronic hepatitis C : Clinical features and prognosis
• Efficacy and Safety of Combination Therapy of Natural Human Interferon Beta and Ribavirin in Chronic Hepatitis C patients
• Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation : A retrospective study of hepatitis C virus-related liver cancer
• Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C
• Factors predictive of sustained virological response following 72 weeks of combination therapy for genotype 1b hepatitis C
• Antiviral effects of peginterferon alpha-2b and ribavirin following 24-week monotherapy of telaprevir in Japanese hepatitis C patients
• Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C Patients with Genotype 1b and Low-virus Load
• The Efficacy of Short-term Interferon-beta Therapy for Chronic Hepatitis C Patients with Low Virus Load
• Natural Human Interferon β Plus Ribavirin Combination Therapy in Japanese Patients Infected with Hepatitis C Virus and a High Viral Load
• Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus
• Prolonged Hepatitis after Acute Infection with Genotype H Hepatitis B Virus
• Long-term efficacy of interferon therapy in patients with chronic hepatitis B virus infection in Japan
• Suitable Treatment Period in Patients with Virological Response during Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis C
• Determinants of the clinical outcome of patients with severe acute exacerbation of chronic hepatitis B virus infection
• Side Effects of Combination Therapy of Peginterferon and Ribavirin for Chronic Hepatitis-C
• Serum KL-6 Level is Elevated in Chronic Hepatitis C Patients with Combination Therapy of Pegylated Interferon and Ribavirin

もっと見る 閉じる

スポンサーリンク